The Lane lab strives to expose and target the abnormal biology that drives blood cancers, particularly those with poor prognoses or without specific treatments. We focus predominantly on acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), and blastic plasmacytoid dendritic cell neoplasm (BPDCN), and the disruption of normal hematopoietic stem cell development in hematologic malignancies.
Our goal is to understand the genetic and epigenetic changes in malignant hematopoietic cells, develop innovative model systems to study those abnormalities, and ultimately discover novel therapeutic strategies. We hope that our research leads to better tolerated therapies and more cures for patients with leukemia and other blood disorders.
We are also committed to training the next generation of physicians and scientists who will be future leaders in cancer research and clinical-translational innovation.